Evidence map›Paper›PMID 24637684›Full record

ArticleAntimicrobial agents and chemotherapy2014

Next science wound gel technology, a novel agent that inhibits biofilm development by gram-positive and gram-negative wound pathogens.

Kyle G Miller, Phat L Tran, Cecily L Haley, Cassandra Kruzek, Jane A Colmer-Hamood, Matt Myntti, Abdul N Hamood

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. AnAntibiotics (Basel, Switzerland) · 2022
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kyle G MillerDepartment of Immunology and Molecular Microbiology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Phat L TranDepartment of Ophthalmology and Visual Sciences, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Cecily L HaleyDepartment of Immunology and Molecular Microbiology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Cassandra KruzekDepartment of Surgery, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Jane A Colmer-HamoodDepartment of Immunology and Molecular Microbiology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA Department of Medical Education, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Matt MynttiNext Science, Jacksonville, Florida, USA.
Abdul N HamoodDepartment of Immunology and Molecular Microbiology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA abdul.hamood@ttuhsc.edu.
Texas Tech University · USTexas Tech University Health Sciences Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Loss of the skin barrier facilitates the colonization of underlying tissues with various bacteria, where they form biofilms that protect them from antibiotics and host responses. Such wounds then become chronically infected. Topical antimicrobials are a major component of chronic wound therapy, yet currently available topical antimicrobials vary in their effectiveness on biofilm-forming pathogens. In this study, we evaluated the efficacy of Next Science wound gel technology (NxtSc), a novel topical agent designed to kill planktonic bacteria, penetrate biofilms, and kill the bacteria within. In vitro quantitative analysis, using strains isolated from wounds, showed that NxtSc inhibited biofilm development by Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae by inhibiting bacterial growth. The gel formulation NxtSc-G5, when applied to biofilms preformed by these pathogens, reduced the numbers of bacteria present by 7 to 8 log10 CFU/disc or CFU/g. In vivo, NxtSc-G5 prevented biofilm formation for 72 h when applied at the time of wounding and infection and eliminated biofilm infection when applied 24 h after wounding and infection. Storage of NxtSc-G5 at room temperature for 9 months did not diminish its efficacy. These results establish that NxtSc is efficacious in vitro and in vivo in preventing infection and biofilm development by different wound pathogens when applied immediately and in eliminating biofilm infection already established by these pathogens. This novel antimicrobial agent, which is nontoxic and has a usefully long shelf life, shows promise as an effective agent for the prevention and treatment of biofilm-related infections.

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsAdministration, TopicalAnimalsAnti-Infective AgentsBiofilmsFemaleGelsKlebsiella InfectionsKlebsiella pneumoniaeMicePseudomonas aeruginosaPseudomonas InfectionsStaphylococcal InfectionsStaphylococcus aureusStaphylococcus epidermidisAnti-Infective AgentsGels

Identifiers

PMID24637684
PMCPMC4068445
OpenAlexW2118620770

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.